(Total Views: 73)
Posted On: 10/22/2023 10:40:47 AM
Post# of 25157
$ALPMY News Article - Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV (enfortumab vedotin-ejfv) and KEYTRUDA (pembrolizumab) in First-Line Advanced Bladder Cancer https://marketwirenews.com/news-releases/grou...53531.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
